索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]高子浚,王宇辰,杨文艺.脂蛋白（a）与动脉粥样硬化性心血管疾病[J].国际心血管病杂志,2024,01:21-24.
点击复制

脂蛋白（a）与动脉粥样硬化性心血管疾病(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2024年01期
页码:
21-24
栏目:
综述
出版日期:
2024-01-22

文章信息/Info

Title:
-
作者:
高子浚; 王宇辰; 杨文艺
200080 上海交通大学医学院附属第一人民医院心血管 病临床医学中心
Author(s):
-
关键词:
动脉粥样硬化性心血管疾病; 脂蛋白（a）; 独立危险因素
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2024.01.007
文献标识码:
-
摘要:
脂蛋白（a）[Lp（a）] 具有促炎、抗纤溶和促进动脉粥样硬化等特点，是动脉 粥样硬化性心血管疾病（ASCVD）的独立危险因素。通过降低Lp（a）水平以减少心血管 事件发生风险的部分新药，已在Ⅰ、Ⅱ期临床试验中表现出良好的安全性和疗效。该文介绍 Lp（a）作为ASCVD 独立危险因素的研究进展。
Abstract:
-

参考文献/References

[1] Libby P, Buring JE, Badimon L, et al. Atherosclerosis[J]. Nat Rev Dis Primers, 2019, 5(1):56.
[2] Colivicchi F, Di Fusco SA, Arca M, et al. Non-high-density lipoprotein cholesterol versus low-density lipoprotein cholesterol in clinical practice: ANMCO position paper[J]. J Cardiovasc Med (Hagerstown), 2021, 22(8):609-617.
[3] 冯仁丰. 脂蛋白（a）检测的标准化[J]. 检验医学, 2017, 32(7):555-560.
[4] Cegla J, France M, Marcovina SM, et al. Lp(a): when and how to measure it[J]. Ann Clin Biochem, 2021, 58(1):16-21.
[5] Khatana C, Saini NK, Chakrabarti S, et al. Mechanistic insights into the oxidized low-density lipoprotein-induced atherosclerosis[J]. Oxid Med Cell Longev, 2020, 2020:5245308.
[6] Enas EA, Varkey B, Dharmarajan TS, et al. Lipoprotein(a): an independent, genetic, and causal factor for cardiovascular disease and acute myocardial infarction[J]. Indian Heart J, 2019, 71(2):99-112.
[7] Cegla J, Neely RDG, France M, et al. HEART UK consensus statement on Lipoprotein(a): a call to action[J]. Atherosclerosis, 2019, 291:62-70.
[8] 北京心脏学会. 脂蛋白（a）与心血管疾病风险关系及临床管 理的专家科学建议[J]. 中国循环杂志, 2021, 36(12):1158-1167.
[9] Cao YX, Zhang HW, Jin JL, et al. Lipoprotein(a) and cardiovascular outcomes in patients with previous myocardial infarction: a prospective cohort study[J]. Thromb Haemost, 2021, 121(9):1161-1168.
[10] Rallidis LS, Pavlakis G, Foscolou A, et al. High levels of lipoprotein (a) and premature acute coronary syndrome[J]. Atherosclerosis, 2018, 269:29-34.
[11] Burgess S, Ference BA, Staley JR, et al. Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a mendelian randomization analysis[J]. JAMA Cardiol, 2018, 3(7):619-627.
[12] Langsted A, Kamstrup PR, Nordestgaard BG. High lipoprotein(a) and high risk of mortality[J]. Eur Heart J, 2019, 40(33):2760- 2770.
[13] O'Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk[J]. Circulation, 2019, 139(12):1483-1492.
[14] Yoon YH, Ahn JM, Kang DY, et al. Association of lipoprotein(a) with recurrent ischemic events following percutaneous coronary intervention[J]. JACC Cardiovasc Interv, 2021, 14(18):2059- 2068.
[15] Forbes CA, Quek RG, Deshpande S, et al. The relationship between Lp(a) and CVD outcomes: a systematic review[J]. Lipids Health Dis, 2016, 15:95.
[16] Jin JL, Cao YX, Zhang HW, et al. Lipoprotein(a) and cardiovascular outcomes in patients with coronary artery disease and prediabetes or diabetes[J]. Diabetes Care, 2019, 42(7):1312- 1318.
[17] Verbeek R, Boekholdt SM, Stoekenbroek RM, et al. Population and assay thresholds for the predictive value of lipoprotein (a) for coronary artery disease: the EPIC-Norfolk Prospective Population Study[J]. J Lipid Res, 2016, 57(4):697-705.
[18] Nestel PJ, Barnes EH, Tonkin AM, et al. Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease[J]. Arterioscler Thromb Vasc Biol, 2013, 33(12):2902-2908.
[19] Patel AP, Wang M, Pirruccello JP, et al. Lp(a) (Lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national biobank[J]. Arterioscler Thromb Vasc Biol, 2021, 41(1):465-474.
[20] HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients[J]. N Engl J Med, 2014, 371(3): 203-212.
[21] Tsimikas S, Gordts PLSM, Nora C, et al. Statin therapy increases lipoprotein(a) levels[J]. Eur Heart J, 2020, 41(24):2275-2284.
[22] 王安, 王治平, 宋丽华. 降低脂蛋白a水平的治疗进展[J]. 国际 心血管病杂志, 2023, 50(3):151-154.
[23] Szarek M, Bittner VA, Aylward P, et al. Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial[J]. Eur Heart J, 2020, 41(44):4245-4255.
[24] Santos RD, Raal FJ, Catapano AL, et al. Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia:results of 4 phase Ⅲ trials[J]. Arterioscler Thromb Vasc Biol, 2015, 35(3):689-699.
[25] Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. Lipoprotein(a) reduction in persons with cardiovascular disease[J]. N Engl J Med, 2020, 382(3):244-255.
[26] Tokgozoglu L, Orringer C, Ginsberg HN, et al. The year in cardiovascular medicine 2021: dyslipidaemia[J]. Eur Heart J, 2022, 43(8):807-817.
[27] Hardy J, Niman S, Goldfaden RF, et al. A review of the clinical pharmacology of pelacarsen: a lipoprotein(a)-lowering agent[J]. Am J Cardiovasc Drugs, 2022, 22(1):47-54.
[28] HPS3/TIMI55–REVEAL Collaborative Group. Effects of anacetrapib in patients with atherosclerotic vascular disease[J]. N Engl J Med, 2017, 377(13):1217-1227.
[29] Ueland T, Kleveland O, Michelsen AE, et al. Serum lipoprotein(a) is not modified by interleukin-6 receptor antagonism or associated with inflammation in non-ST-elevation myocardial infarction[J]. Int J Cardiol, 2019, 274:348-350.
[30] Cuchel M, Meagher EA, du Toit Theron H, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study[J]. Lancet, 2013, 381(9860):40-46.
[31] Sahebkar A, Simental-Mendía LE, Stefanutti C, et al. Supplementation with coenzyme Q10 reduces plasma lipoprotein(a) concentrations but not other lipid indices: a systematic review and meta-analysis[J]. Pharmacol Res, 2016, 105:198-209.
[32] Eraikhuemen N, Lazaridis D, Dutton MT. Emerging pharmacotherapy to reduce elevated lipoprotein(a) plasma levels[J]. Am J Cardiovasc Drugs, 2021, 21(3):255-265.

备注/Memo

备注/Memo:
基金项目：上海市科学技术委员会探索者计划（21TS1400300）； 上海市科学技术委员会浦江人才计划A 类（20PJ1412700）；上海 交通大学医学院附属第一人民医院院级临床研究课题（CTCCR- 2019B04）
通信作者：杨文艺， E-mail：wenyi.yang@shgh.cn
更新日期/Last Update: 2024-01-22